SMS PHARMACEUTICALS LTD.

SMS Pharmaceuticals Ltd is dispatching a letter with a web-link and QR code for its Integrated Annual Report for FY 2025-26 to shareholders whose email addresses are not registered. The company has also scheduled its 38th Annual General Meeting (AGM) for Tuesday, September 29, 2026, at 10:30 AM IST, to be held via Video Conference (VC) / Other Audio-Visual Means (OAVM). Shareholders are reminded to update PAN and KYC details by September 22, 2026, to be eligible for the proposed dividend of ₹0.40 per equity share.

SMS Pharmaceuticals Ltd has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report, which is part of the Annual Report, details the company's corporate identity, business activities, operations, and employee data. Key disclosures include the company's CIN, registered office, contact details, and stock exchange listings on BSE and NSE. The company's primary business activity is the manufacture of Active Pharmaceutical Ingredients (APIs), accounting for 99.21% of its turnover. Exports contribute 66% of the total turnover, serving a diverse range of pharmaceutical companies worldwide. The report also provides employee statistics, including permanent and non-permanent staff, and details on gender representation. The BRSR is prepared on a standalone basis.

SMS Pharmaceuticals Ltd has announced its 38th Annual General Meeting (AGM) for the financial year 2025-26. The meeting is scheduled to be held on Tuesday, September 29, 2026, at 10:30 a.m. IST via Video Conferencing. The company will dispatch the Notice of AGM and the Annual Report for FY 2025-26 to its members. Key dates for shareholders include a Record Date of September 22, 2026, for dividend eligibility and AGM attendance, with remote e-voting available from September 25 to September 28, 2026. The Annual Report is also accessible on the company's website.

SMS Pharmaceuticals Ltd has announced its 38th Annual General Meeting (AGM) scheduled for Tuesday, September 29, 2026, at 10:30 a.m. IST. The meeting will be conducted via Video Conferencing. The company has also released its Annual Report for the Financial Year 2025-26, which is available on its website and being dispatched to shareholders. Key dates include a Record Date of September 22, 2026, for dividend purposes and e-voting eligibility, with remote e-voting open from September 25 to September 28, 2026. The report highlights the company's strategy of Innovating, Expanding, and Diversifying.

SMS Pharmaceuticals Ltd has announced a revision to its dividend record date, moving it from September 16, 2026, to September 22, 2026. This change is due to unavoidable circumstances, administrative, and scheduling constraints, which also led to a revised date for the 38th Annual General Meeting (AGM). The AGM will now be held on September 29, 2026, and the book closure period is from September 23 to September 29, 2026. The revised record date of September 22, 2026, is for determining members eligible to receive the dividend for the financial year 2025-26, subject to approval at the AGM.

SMS Pharmaceuticals Ltd has announced a change in the date of its 38th Annual General Meeting (AGM) from September 23, 2026, to September 29, 2026. This rescheduling is due to unavoidable circumstances, administrative, and scheduling constraints. Consequently, the record date for dividend eligibility has been revised to September 22, 2026, from September 16, 2026. The book closure period will now be from September 23, 2026, to September 29, 2026. The AGM will be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM).

SMS Pharmaceuticals Ltd announced that its Board of Directors has recommended a final dividend of ₹0.40 per equity share for the financial year ended March 31, 2026. This recommendation is subject to shareholder approval at the 38th Annual General Meeting scheduled for September 23, 2026. The company has fixed September 16, 2026, as the record date for determining dividend entitlement. The dividend payment, if approved, will be made after September 23, 2026, with applicable TDS deductions. The filing also details TDS provisions for resident and non-resident shareholders, including rates and documentation requirements for exemptions.

SMS Pharmaceuticals Ltd reported unaudited financial results for the quarter ended June 30, 2026. Revenue from operations increased by 6% year-on-year to ₹207.0 crore, driven by broad-based growth in high-value APIs. Gross margin remained strong above 45%, and EBITDA margin was sustained at approximately 20%. Profit After Tax (PAT) saw an 8% YoY increase. The company completed 4 DMF/CEP filings and is on track to meet its FY27 target. A ₹280 crore capex program is progressing as planned, and the company approved an infusion of up to ₹50 crore as a loan into its subsidiary, SMS Peptides Private Limited. The R&D team strength increased to 200.

SMS Pharmaceuticals Ltd's Board of Directors met on July 31, 2026, approving the standalone and consolidated un-audited financial results for the first quarter ended June 30, 2026. The company reported total income of ₹20,870.93 Lakhs and a profit before tax of ₹2,814.42 Lakhs for the quarter. The 38th Annual General Meeting is scheduled for September 23, 2026. Key decisions also included the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director for five years, subject to shareholder approval, and approval to provide a loan of up to ₹50 Crores to its subsidiary, SMS Peptides Private Limited.

SMS Pharmaceuticals Ltd announced the fixation of the record date as September 16, 2026, for determining eligible members to receive dividends for FY 2025-26, subject to AGM approval. The company's 38th Annual General Meeting is scheduled for September 23, 2026. The Board also approved un-audited standalone and consolidated financial results for Q1 FY26, showing a profit before tax of ₹2,814.42 Lakhs. Additionally, the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director for five years from October 1, 2026, was approved, pending shareholder consent. The company also plans to provide a loan of up to ₹50 Crores to its subsidiary, SMS Peptides Private Limited.